1) Investigación >
Artículos Publicados >

Por favor, use este identificador para citar o enlazar este ítem:

Título : N -Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-
Autor : Rodrigues, Juan
Charris, Jaime
Camacho, José
Barazarte, Arthur
Gamboa, Neira
Nitzsche, Bianca
Hopfner, Michael
Lein, Michael
Jung, Klaus
Abramjuk, Claudia
Palabras clave : anti-tumour effect; benzothiazole derivatives;neoangiogenesis; prostate cancer
Fecha de publicación : 21-Sep-2012
Editorial : Journal of Pharmacy and Pharmacology 65, 411-422, 2013
Resumen : Objectives Benzothiazoles (BZTs) represent organic compounds with different biological actions. In this study we aimed to investigate ten newly synthesized BZT derivatives as potential anti-tumour agents against prostate cancer in vitro and in vivo. Methods The cytotoxic effect of these compounds was screened on the human prostate cancer cell lines PC-3 and LNCaP. The most effective compound, N′-formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide, was further characterized regarding its dose- and time-dependent effects on cell viability and proliferation (XTT test) as well as on adhesion and spreading (real-time cell analyzer xCelligence), migration (scratch-wound repair assay) and invasion (Boyden chamber) of the cells. This BZT derivative was also tested as an inhibitor of angiogenesis (chicken chorioallantoic membrane assay), clonogenic activity (soft agar) and matrix metalloproteinase 9 (gelatin zymography). Key findings N′-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide significantly inhibited all tested properties of the prostate cancer cell lines and showed low toxic in vitro and in vivo effects. The in vitro anti-tumour activity of this compound was confirmed by the in vivo effects on PC-3 xenografts in nude mice. Tumour growth was decreased in treated compared with untreated mice. Conclusions These results suggest the potential capacity of BZTs and in particular N′-formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as antitumour agents for the treatment of prostate cancer.
ISSN : doi: 10.1111/j.2042-7158.2012.01607
Aparece en las colecciones: Artículos Publicados

Ficheros en este ítem:

Fichero Descripción Tamaño Formato
JPharmPharmacol_2013_65_411-422.pdf596.81 kBAdobe PDFVisualizar/Abrir

Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2008 MIT and Hewlett-Packard - Comentarios